S BioScience business.

‘The improvement made so far in the advancement of Aes-103 demonstrates NCATS' catalytic function in bringing together the required players, whether academic, non-profit or industry, to get over obstacles to translation and progress badly needed remedies to patients.’ Individuals coping with sickle cell disease possess defective hemoglobin, the proteins in red bloodstream cells that bears oxygen. This defect causes their cells to be crescent-shaped and rigid, blocking small arteries and causing inflammation, strokes and pain, and decreased blood circulation. Aes-103 functions by binding to hemoglobin and changing its structure straight, thereby reducing the sickling of red bloodstream cells.ArQule prices underwritten public offering of 7,150,000 shares of common stock ArQule, Inc. today announced the pricing of an underwritten public offering of 7,150,000 shares of its common stock at a cost of $7.30 per share. The net proceeds to ArQule from the sale of the shares, after deducting underwriting special discounts and commissions and estimated expenses, are expected to be approximately $48.7 million. The about April 16 offering is likely to close on or, 2012, subject to customary closing conditions. Leerink and Citigroup Swann are performing as joint book-running managers for the offering. Lazard Capital Markets, RBC Capital Marketplaces and Oppenheimer & Co. Are acting as co-managers. ArQule provides granted the underwriters a 30-time option to buy up to an additional 1,072,500 shares of common share.